Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 28, 2026
Celestica (CLS) Delivers Strong Q2 Beat with +62% Revenue Growth

Celestica (CLS) Delivers Strong Q2 Beat with +62% Revenue Growth

Key Takeaways

  • Revenue exceeded all expectations: Q2 2026 revenue reached $4.70 billion, up 62% year-over-year and well above the company's own guidance range of $4.15 billion to $4.45 billion.
  • Adjusted EPS (earnings per share) crushed consensus: Adjusted EPS of $2.54 handily beat analyst estimates of approximately $2.29 to $2.31 and surpassed the high end of management's guidance of $2.14 to $2.34.
  • Adjusted operating margin hit a new company record of 8.2%, up from 7.4% in the same quarter last year, reflecting strong operating leverage.
  • Connectivity & Cloud Solutions (CCS) segment revenue jumped 84% year-over-year to $3.81 billion, now representing 81% of total company revenue and underscoring the hyperscaler-driven AI infrastructure boom.
  • Full-year 2026 guidance was raised significantly: Revenue outlook lifted to $20.5 billion and adjusted EPS outlook raised to $11.30, with management signaling growth acceleration in 2027.
  • Stock surged in after-hours trading: Shares rose over 7% in extended trading following the report, adding to a 5.2% gain during the regular session.

Why Celestica's Results Matter Right Now

Celestica's Q2 2026 earnings, released after the close on July 27, came at an important juncture for the electronics manufacturing services sector. As a key supplier of data center infrastructure, the company stands to benefit from ongoing AI-related capital spending. Shares had already declined about 36% from the 52-week high of $474.02 ahead of the report, so investors were particularly focused on whether demand momentum could hold. The CCS segment, driven by hyperscale cloud providers building out AI capacity, was the main area to watch. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. This quarter served as a useful test of Celestica's ability to scale revenue profitably while navigating supply chain issues.

What the Numbers Showed

The results came in well ahead of expectations across the board. Revenue reached $4.70 billion, a 62% increase from $2.89 billion in Q2 2025. That figure cleared both the consensus range of roughly $4.38 billion to $4.39 billion and the top end of the company's own guidance. On the bottom line, GAAP diluted EPS was $3.17 versus $1.82 a year earlier. Adjusted EPS of $2.54 exceeded analyst estimates of about $2.29 to $2.31 and management's range of $2.14 to $2.34. Net earnings totaled $368.8 million.

Margins also improved. GAAP operating margin rose to 9.8% from 9.4%, while adjusted operating margin reached a record 8.2%, up from 7.4%. The CCS segment remained the standout, with revenue climbing 84% to $3.81 billion and segment margin expanding to 8.7% from 8.3%. Hardware Platform Solutions revenue within CCS grew 58% to around $1.9 billion. The ATS segment grew a steadier 8% to $0.89 billion, with margin improving to 6.3% from 5.3%.

How the Market Reacted

Investors responded positively. Shares finished the regular session at $321.06, up 5.2%, then rose another 7.2% in after-hours trading to around $344. The move reflected both the size of the beat and the upward revision to full-year guidance. Sentiment had been measured before the print, partly due to the prior pullback and concerns around component availability. Management pointed to stronger second-half forecasts and better component supply as reasons for the raised outlook. The after-hours reaction suggested many viewed the results as confirmation of Celestica's position in the AI buildout.

Looking Ahead and What to Watch

Guidance for the rest of the year points to continued momentum. For Q3, Celestica expects revenue of $5.25 billion to $5.55 billion and adjusted EPS of $2.88 to $3.08. Full-year revenue guidance moved to $20.5 billion from $19.0 billion, with adjusted EPS lifted to $11.30 from $10.15. Free cash flow guidance increased to $600 million from $500 million, and the adjusted operating margin target rose to 8.4%.

CEO Rob Mionis noted that revenue growth should accelerate beyond the 65% rate expected for 2026, supported by robust demand and new programs. Adjusted EPS is projected to grow even faster than revenue in 2027, helped by margin expansion. Key areas to monitor include customer concentration in the CCS business, supply chain conditions for custom silicon and memory, and free cash flow discipline amid higher capital spending. The combination of a strong backlog, improving margins, and higher growth expectations leaves Celestica well positioned in the current environment.

Refining My Analysis with AI Tools

When evaluating stocks in the AI infrastructure space like this one, I find Tickeron’s AI Screener helpful for quickly applying filters on technical patterns, fundamentals, and industry trends. It allows me to compare opportunities across the sector more efficiently than manual reviews and has become a regular part of my process for spotting relative strength or emerging setups.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CLS

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


Momentum Indicator for CLS turns negative, indicating new downward trend

CLS saw its Momentum Indicator move below the 0 level on August 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 76 similar instances where the indicator turned negative. In of the 76 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 66 cases where CLS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

CLS moved below its 50-day moving average on August 06, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CLS broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for CLS entered a downward trend on July 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CLS's RSI Oscillator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for CLS just turned positive on July 28, 2026. Looking at past instances where CLS's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CLS advanced for three days, in of 368 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 65, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. CLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: CLS's P/B Ratio (14.577) is slightly higher than the industry average of (6.338). P/E Ratio (36.403) is within average values for comparable stocks, (95.908). CLS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.341). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (2.605) is also within normal values, averaging (5.350).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

Notable companies

The most notable companies in this group are Corning (NYSE:GLW), Universal Display Corp (NASDAQ:OLED).

Industry description

The Electronic Components industry produces electronic equipment for industries and consumer electronics products, such as mobile devices, televisions, and circuit boards. TE Connectivity Ltd, for example, is a company that designs and manufactures connectivity and sensor products for harsh environments in various industries, such as automotive, industrial equipment, aerospace, and oil & gas. Another major player, Corning Inc., makes advanced optics including end-to-end fiber and wireless solutions for communications networks along with various other technologies catering to industrial and scientific applications.

Market Cap

The average market capitalization across the Electronic Components Industry is 14.12B. The market cap for tickers in the group ranges from 669 to 210.36B. APH holds the highest valuation in this group at 210.36B. The lowest valued company is MMATQ at 669.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Components Industry was 11%. For the same Industry, the average monthly price growth was 1%, and the average quarterly price growth was 17%. GAUZ experienced the highest price growth at 42%, while CLS experienced the biggest fall at -11%.

Volume

The average weekly volume growth across all stocks in the Electronic Components Industry was 208%. For the same stocks of the Industry, the average monthly volume growth was 306% and the average quarterly volume growth was 195%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 47
Price Growth Rating: 49
SMR Rating: 73
Profit Risk Rating: 65
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
CLS
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a provider of electronics manufacturing services

Industry ElectronicComponents

Profile
Details
Industry
Electronic Components
Address
5140 Yonge Street
Phone
+1 416 448-5800
Employees
26554
Web
https://www.celestica.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Celestica (CLS) Delivers Strong Q2 Beat with +62% Revenue Growth